Loading
A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, now recruiting.
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07003074, led by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) Positive Recurrent or Metastatic Breast Cancer. Planned enrolment is 642 participants (estimated). The study started in 2025-06-23 and primary completion is expected in 2029-07. No results have been posted on ClinicalTrials.gov.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer.